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Abstract
Background: Use of selective serotonin reuptake inhibitors (SSRI) during pregnancy is common while the effect on the
infant’s neurological outcome is unknown. Our objective was to determine the effects of prenatal SSRI-exposure on the
infants’ neurological functioning, adjusted for maternal mental health.
Methods: A prospective observational study from May 2007 to April 2010. The study groups comprised 63 SSRI-exposed
infants (SSRI group) and 44 non-exposed infants (non-SSRI group). Maternal depression and anxiety were measured using
questionnaires. The main outcome measures during the first week after birth and at three to four months were the quality
of the infants’ general movements (GMs) according to Prechtl and a detailed motor optimality score. We calculated odds
ratios (ORs) and 95% confidence intervals (CIs) for abnormal GM quality in the SSRI and non-SSRI groups, and adjusted for
maternal depression, anxiety, and other confounders. The study was registered under 53506435 in the ISRCTN.
Findings: All infants were born around term. During the first week, abnormal GMs occurred more frequently in the SSRI
group than in the non-SSRI group (59% versus 33%) and the median MOS was lower (13 versus 18). The OR for abnormal
GMs in the SSRI versus the non-SSRI group was 3?0 (95% CI, 1.3 to 6.9) and increased after adjustment for confounders. At
three to four months, more SSRI-exposed infants had monotonous movements (48% versus 20%) with lower median MOSs
(26 versus 28). The OR for monotonous movements was 3?5 (95% CI, 1.5 to 8.6) and increased after adjusting for
confounders.
Interpretation: Prenatal exposure to SSRI had an adverse effect on early neurological functioning as reflected by GM quality,
irrespective of maternal depression and anxiety, and other confounders. Physicians should take this into account in
consultation with parents.
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Introduction
Women’s mental health problems during pregnancy are
associated with adverse consequences for their infants, such as
preterm birth, low birth weight, and may have long-term
behavioural and developmental problems.[1–3] Since approxi-
mately 10% to 25% of pregnant women fulfil the diagnostic
criteria for depression[1,4,5] and 7% to 18% those for anxiety
disorder[6,7], neonatal consequences of maternal mental health
problems may have major effects on child health and develop-
ment. Improved understanding of the influence of maternal
depression on adverse outcome of pregnancies has resulted in
prescription rates of antidepressant medication during pregnancy
ranging from 2.0% in the Netherlands to 13.4% in the USA.[8,9]
Of all the antidepressants, selective serotonin reuptake inhibitors
(SSRIs) are used most frequently.[8,9] Since SSRIs readily cross
the placenta [10] concern has risen about the short-term and long-
term effects of prenatal exposure to SSRIs on the developing
foetus.[4,11–16].
We initiated an extensive prospective study, the Dutch SMOK
trial (SSRIs in pregnant mothers, outcome of the kids) on the
effects of exposure to SSRIs during pregnancy on the motor and
cognitive outcome of children up to seven years of age. In the part
of the study presented here, our aim was to determine the effects of
prenatal SSRI exposure on early neurological functioning of the
infant, adjusted for maternal mental health.
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Methods
Study Design and Setting
We performed a prospective observational study on 107
mother-infant pairs from the catchment areas of two level-two
hospitals in the northern part of the Netherlands (Medical Centre
Leeuwarden and Wilhelmina Hospital Assen) and the nearby
midwifery practices. This rural study area has a birth rate of about
2500 births per year. The study period was from May 2007 to
April 2010.
Although our study was observational, it is registered with the
Netherlands National Trial Registry under number 740, and its
international standard randomised controlled trial number
(ISRCTN) is 53506435.
Ethics Statement
All parents (both mothers and fathers) gave their written
informed consent on behalf of their infants. The Medical Ethics
Committee of University Medical Center Groningen, the Nether-
lands, approved the study protocol and the consent procedure.
Participants
Initially the study comprised three study groups (Figure 1): 1.
SSRI group. 2. Depression and/or anxiety group unmedicated. 3.
Controls. During the inclusion process it appeared that the
number of pregnant women who were referred to the second study
group was low (two out of the nine women who said to have been
diagnosed with depression and/or anxiety did not have a high
score for depression or anxiety on the assessment questionnair-
es).The healthy control group appeared to also comprise women
who had a positive score on depression or anxiety. We therefore
merged the second and third groups into one non-SSRI group that
consisted of pregnant women who did not use a SSRI. Inclusion
was open. Women, in any stage of pregnancy and n both groups,
were either self-referred, after reading about our study in the local
newspapers, or referred by their gynaecologist, psychiatrist,
midwife, or general practitioner).
The inclusion criteria for the SSRI group were SSRI treatment
for depression and/or anxiety disorder during pregnancy and
already taking medication before conception. Venlafaxine was
considered to work as an SSRI if being dosed low [17,18]; women
using venlafaxine ,200 mg were included in the SSRI group.
Women, who had stopped taking medication before labour,
remained in the SSRI group because they had taken SSRIs during
the first trimester. The exclusion criteria were the use of
psychotropic drugs other than SSRIs, anti-epileptic drugs, and
multiple congenital anomalies of the infant. The inclusion criteria
for the non-SSRI group were no psychotropic medication during
pregnancy whatsoever. Exclusion criteria were the use of anti-
epileptic drugs and multiple congenital anomalies of the infant.
Out of the 111 women initially included, one woman had a
miscarriage, two women were lost to follow-up, and one child had
multiple congenital anomalies (Figure 1). This resulted in 107
mother-infant pairs studied prospectively: 63 infants in the SSRI
group and 44 infants in the non-SSRI group.
We had estimated that we needed to include at least 105 infants
to be able to study the effects of SSRIs with two reference groups
(i.e. two dummy variables) and five potential confounding
variables on our primary outcome measure. This would yield
seven dichotomous variables with 15 participants per comparison.
This was a conservative estimate of ten events per dichotomized
predictive variable plus a 50% buffer. [19].
Measures and Procedures
SSRI medication. To be able to compare the doses of the
different types of SSRIs that were used, we expressed these in dose
equivalents as multiples of the standard Defined Daily Dose
(DDD). [20] One DDD of the SSRIs used in this study was 20 mg
for paroxetine, fluoxetine, and citalopram; 50 mg for sertraline;
and 100 mg for venlafaxine. The dose equivalent was set to 1 to
indicate standard exposure. For example, the dose equivalent was
2 for a woman using 40 mg of paroxetine per day.
Assessment of neurological functioning. We used the
method of assessing neurological functioning by assessing the
quality of an infant’s general movements (GMs) as developed by
Prechtl [21] (see File S1). Two digital video recordings were made
of each infant between days two and seven after birth, and again at
three to four months. The recordings were made at the outpatient
clinic or at home by either author CV or our research assistant.
The infants lay partly dressed and supine. A recording of at least 5
minutes was made while the infant was in Prechtl’s state 4 (quiet
wakefulness). [22] NV analysed the GMs offline according to
Prechtl’s method. Although interrater reliability of GM assessment
is high (89% to 93%) [21], in case of doubt, author AB was
consulted to make the definitive judgment. NV and AB were blind
as to the infants’ exposure status to SSRI.
Primary outcome measures: GMs and motor optimality
score during the first week and at three to four months after
term. The primary outcome measures were GM quality and a
detailed motor optimality score (MOS) according to Prechtl’s
optimality concept.[21,23–25] The overall quality of the GM of
the first recording was scored as either ‘‘normal’’ or ‘‘abnor-
mal’’.[21,24] In case it was of abnormal we also scored whether
the GMs were ‘‘poor repertoire’’ (PR), ‘‘chaotic’’ (Ch), ‘‘chaotic
features’’ (ChF= infants with poor repertoire GMs with chaotic
episodes), or ‘‘cramped synchronized’’ (CS). [24] Next, we assessed
the MOS, which is based on a detailed analysis of the quality of
the GMs on a continuous scale. The domains of the MOS at this
age are overall quality (normal, PR, Ch, or CS), sequence,
amplitude, speed, space, rotational components, onset/offset, and
tremulous movements.[21,24] The highest and most optimal score
is 18, the lowest score is 8.
Overall GM quality of the second recording at three to four
months was assessed as normal (which is the norm) or abnormal
fidgety movements (FMs). Next, we assessed the concurrent motor
repertoire in order to obtain a MOS. The domains of the MOS at
this age are age-adequacy of the concurrent motor repertoire,
presence and normality of individual movement patterns, presence
and normality of individual postural patterns, and the nature of
the movements of the concurrent repertoire (monotonous or not).
The highest and most optimal score is 28, the lowest score is
5.[21,26] Reduced complexity of the concurrent motor repertoire,
resulting in monotonous movement, is related to minor neurolog-
ical dysfunction in preterm infants. [23] We chose, therefore, to
allocate a separate score for ‘‘monotonous movements’’.
Other determinants: depression and anxiety. We assess-
ed maternal depression and anxiety during the third trimester of
pregnancy using the Beck Depression Inventory (BDI) [27] and
the State Trait Anxiety Inventory (STAI) [7] for adults. At the
infants’ age of three to four months, we re-assessed maternal
depression and anxiety along with paternal depression and
anxiety. The BDI is a self-reported questionnaire of 21 items
measuring depressive symptoms (scores 0 to 63). Depression is
defined by a BDI score of $13. [27] The STAI is a self-reported,
20-item questionnaire measuring temporary anxiety state condi-
tions (STAI-S) and anxiety trait conditions (STAI-T) (scores 20 to
80). We chose to only use the STAI-S, assuming an anxiety state to
Early Neurological Outcome of SSRI Exposed Infants
PLOS ONE | www.plosone.org 2 May 2013 | Volume 8 | Issue 5 | e64654
be a possible reason for using SSRIs. Anxiety state, hereinafter
referred to as ‘‘anxiety’’, was defined as a STAI-S score of .40.
[7].
Statistical Analysis
Data were analysed using SPSS 19. We first assessed the
background characteristics of the women in the SSRI and non-
SSRI groups. Second, we assessed the association of SSRI
exposure with the quality of the infants’ GMs during the first
week (abnormal/normal) and at three to four months of age
(monotonous movements/no monotonous movements). For the
MOS we used the Mann-Whitney test. Subsequently, we assessed
the association of SSRI exposure with abnormal GM quality
during the infants’ first week and monotonous GMs at three to
four months by calculating odds ratios (ORs).
We adjusted for possible confounders and calculated adjusted
ORs (aORs) by using a multivariate logistic regression model. The
confounders we considered were maternal depression and anxiety
during the third trimester of pregnancy, low-level maternal
education (lower than vocational education), low gestational age
(below 38 weeks), low birth weight (below 2750 g), and sex. For the
GMs at the age of three to four months we also considered
paternal depression and anxiety as possible confounders. Because
depression and anxiety overlap, we constructed two models: we
entered only one of the entities regarding maternal mood in each
model apart from the other confounders, giving aORdepr+ and




In Table 1 we present the background characteristics and other
determinants including those related to depression and/or anxiety.
There was an overlap in the type of mood disorder. In the SSRI
group only 3% of the women had depression, 22% had anxiety,
and 20% had both. In the non-SSRI group this was 0%, 3%, and
21%, respectively.
The BDI score during pregnancy correlated highly with the
BDI score at the infants’ age of three to four months (Spearman’s
rho= 0.62; p,.001); the same was true for the STAI-S score
(Spearman’s rho= 0.72; p,.001).
One of the two infants with a low Apgar score had a normal
umbilical pH and fully recovered after several days. The other
infant suffered from birth asphyxia with Apgar scores of 0 and 0
after 1 and 5 minutes. This infant received hypothermia treatment
at a tertiary neonatal intensive care centre and was hospitalised for
several weeks. Of the remaining infants the first three months were
uneventful considering diseases that might influence neurological
functioning like meningitis, sepsis, or neurotrauma.
Characteristics of SSRI Medication
In Table 2 we present the data about the type of SSRI
medication, daily doses and dose equivalents.
Assessments of Neurological Outcomes
For 107 infants, 209 recordings were made out of the planned
214. In the SSRI group we missed making five recordings in the
first week due to either the parents or the nurses forgetting to
Figure 1. Flow sheet of inclusion and exclusion. A+= anxiety. A2=no anxiety. BDI = Beck Depression Inventory. D+=depression. D2=no
depression. GM=general movement. STAI-S = State Trait Anxiety Inventory - State.
doi:10.1371/journal.pone.0064654.g001
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inform us of the infant’s birth. The median age (minimum-
maximum) at first recording was the same for both groups, i.e. 3.0
days (2–7). The postnatal age in weeks after term at second
recording for the SSRI group was 14.0 (12–20) and 14.0 (11–17)
for the non-SSRI group.
Neurological Outcome as Assessed by GMs in Relation to
SSRI Exposure
GM quality during the first week. Table 3 shows that
abnormal GMs during the first week were observed nearly twice as
often in the SSRI as in the non-SSRI group. The crude OR for
abnormal GMs in the SSRI versus the non-SSRI group was 3.0
(95%CI, 1.3–6.9, p= .008) (Table 4).
ChF GMs were seen more often in the SSRI than in the non-
SSRI group (Table 3). Chaotic GMs were rare and only seen in
the SSRI group.
The MOSs were significantly lower in the SSRI group, and
scores on all subdomains were more often abnormal. The range of
amplitude abnormalities was either too small or too large.
Similarly, speed abnormalities were also either too low or too high.
In the SSRI group, a lower MOS was associated with a higher
dose equivalent (Spearman’s Rho 20.361, p=0.005).
GM quality at three to four months. At the age of three to
four months only three infants had abnormal FMs (Table 3). All
three belonged to the SSRI group. MOSs were significantly lower
in the SSRI group. The concurrent repertoire showed monoto-
nous GMs significantly more often in the SSRI group. The crude
OR for monotonous movements in the SSRI group versus the
non-SSRI group was 3.5 (95%CI, 1.5–8.6, p= .005) (Table 4).
Table 1. Background characteristics of women and infants.
SSRI group (n =63) Non-SSRI group (n =44)
Women’s general characteristics
Age at labour, years, median (min-max) 31 (21–42) 32 (22–39)
Caesarean section, n (%) 6 (10) 4 (9)
Low-level education*, n (%) 26/57 (46) 17/43 (40)
Smoking, n (%) 11/58 (19) 4/43 (9)
Cigarettes per day among smokers, median (min-max) 6 (1–20) 5 (5–10)
Alcohol use .2 units/wk, n (%) 3/61 (5) 0/42 (0)
Maternal psychopathology during pregnancy
BDI score, median (min-max) 7 (0–34) 4 (0–35)
Depression, n (%) 14/61 (23) 9 (21)
STAI-S score, median (min-max) 37 (20–76) 30 (20–72)
Anxiety state, n (%) 23/61 (38) 10 (23)
Maternal psychopathology at infant’s age 3–4 months
BDI score, median (min-max) 6 (0–32) 3 (0–27)
Depression, n (%) 15/59 (25) 6 (14)
STAI-S score, median (min-max) 34 (21–68) 26 (20–75)
Anxiety state, n (%) 23/59 (39) 7 (16)
Infants’ general characteristics
Male sex, n (%) 27 (43) 22 (50)
Gestational age, weeks, median (min-max) 39?1 (36?7–42?7) 40?0 (37?3–41?7)
Preterm, n (%) 2 (3) 0 (0)
Birth weight, grams, median (min-max) 3455 (2225–5500) 3830 (2500–4750)
Birth weight ,p10, n (%) 10 (16) 3 (7)
Apgar score #5 at 5 min, n (%) 2 (3) 0 (0)
Breastfed, n (%) 25/59 (42) –
Breastfed .50% in months, median (min-max)` 4 (1–14) –
Paternal psychopathology at infant’s age 3 to 4 months
BDI score, median (min-max) 1 (0–19) 1 (0–10)
Depression, n (%) 4/52 (8) 0/42 (0)
STAI-S score, median (min-max) 26 (20–58) 29 (20–48)
Anxiety state, n (%) 8/50 (16) 6/41 (15)
2not applicable.
*low-level education = educational level lower than vocational education.
`The number of months the infant received more than 50% of the total amount of milk from breastmilk.
BDI = Beck Depression Inventory.
STAI-S = State Trait Anxiety Inventory-State.
doi:10.1371/journal.pone.0064654.t001
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In the non-SSRI group MOS during the first week related to
MOS at three to four months (Spearman’s rho 0.305, p=0.044).
This was not the case in the SSRI group.
In the SSRI group, the MOS was not related to the dose
equivalent.
Motor Performance in Relation to Confounders
Table 4 shows the ORs for abnormal GMs in the SSRI versus
the non-SSRI group after adjusting for potential confounders.
Figure 2 illustrates the median MOS during the first week
(Figures 2A and 2B) and at three to four months (Figures2C and
2D) in the SSRI and non-SSRI groups categorized according to
maternal depression and anxiety.
Table 2. Characteristics of SSRI medication.
Type of SSRI used n (%) Daily dose (range)
Dose equivalent*
(range) n (%) below/equal/above DDD**
Paroxetine 27 (43) 10–40 0.5–2 5 (19)/18 (67)/4 (15)
Cipramil 14 (22) 10–30 0.5–1.5 2 (14)/11 (79)/1 (7)
Venlafaxine 10 (16) 37.5–150 0.38–1.5 3 (30)/0 (0)/7 (70)
Fluoxetine 8 (13) 10–40 0.5–2 2 (25)/5 (63)/1 (13)
Sertraline 2 (3) 50–100 1–2 0 (0)/1 (50)/1 (50)
Changed medication 2 (3)
Stopped medication 4 (6)
*Dose equivalent =Daily dose divided by Defined Daily Dose.
**DDD=Defined Daily Dose: paroxetine = 20 mg; cipramil = 20 mg; venlafaxine = 100 mg; fluoxetine = 20 mg; sertraline = 50 mg.(20).
doi:10.1371/journal.pone.0064654.t002
Table 3. Motor performance in the SSRI and non-SSRI group of infants.





GMs during first week
GM quality n= 58* n= 44
Abnormal, n (%) 34 (59) 14 (33) 0.009
Poor repertoire, n (%) 30 (52) 14 (33) 0.11
Chaotic, n (%) / ChF, n (%) 4 (7) / 11 (19) 0 (0) / 1 (2) 0.14 / 0.012
Cramped synchronized, n (%) 0 (0) 0 (0)
MOS, median (min-max) 13 (9-18) 18 (10-18) ,0.001`
Monotonous sequence, n (%) 36 (62) 13 (30) 0.001
Amplitude abnormalities, n (%) 13 (22) 3 (7) 0.052
Speed abnormalities, n (%) 26 (45) 16 (36%) 0.042
Not using up full space, n (%) 11 (19) 0 (0) 0.002
No rotations, or jus a few, n (%) 28 (31) 7 (16) 0.001
Abrupt onset and/or offset, n (%) 16 (28) 5 (11) 0.051
Tremulous movements, n (%) 35 (60) 13 (30) 0.012
GMs at 3 to 4 months of age
GM quality n= 63 n= 44
Abnormal quality, n (%) 3 (5) 0 (0) 0.27`
Abnormal fidgety, n (%) 2 (3) 0 (0)
Absent fidgety, n (%) 1 (2) 0 (0)
MOS, median (min-max) 26 (7–28) 28 (21–28) 0.035``
Monotonous movements, n (%) 30 (48) 9 (20) 0.005`
ChF = Chaotic features.
GM = general movement.
MOS = motor optimality score.
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Discussion
We demonstrated that prenatal SSRI exposure has a negative
effect on the quality of GMs and as such it is a reflection of the
negative effect these antidepressants have on early neurological
outcome. SSRI exposure was strongly associated with abnormal
GMs and lower MOSs during the first week after birth, and a
monotonous motor repertoire and lower MOSs at the age of three
to four months. This association became even more pronounced
after we had adjusted for the confounders maternal depression and
anxiety, maternal education, the infants’ gestational age, birth
weight and sex, and paternal depression and anxiety.
Neurological effects of prenatal SSRI exposure could be due to
serotonin withdrawal, to direct serotonergic effects, or to
teratogenic effects of the SSRI on the foetal brain. Since the
motor repertoire during the first week was not associated with the
motor repertoire at three to four months in the SSRI group, we
speculated that the effects observed during the first week were
possibly due to all of the above mentioned factors, while the effects
seen at three to four months were probably due to permanent
teratogenic effects of the SSRI on the developing brain.
In the first week, we observed a different spectrum of symptoms
in SSRI-exposed infants than in the non-exposed group that was
dose-related. This spectrum has been variously named SSRI-
induced neonatal-behaviour-syndrome, poor neonatal adaptation,
or prenatal antidepressant exposure syndrome.[10,14,15,28–31]
In SSRI-exposed foetuses, a dose-related response was also found
by Mulder et al. [32] They reported that abnormal foetal
neurobehavioral development throughout gestation was associated
with standard and high doses of SSRIs. [32].
Of special interest to us was the dualism of disturbances in GMs
between the infants, i.e. monotonous movements and few rotations
on the one hand, and tremulous movements and chaotic features
on the other hand. Moreover, both high and low amplitudes and
speeds were seen in SSRI-exposed infants. Zeskind et al. described
both lower arousal (under-stimulation) and higher arousal
(hyperexcitability) in such neonates. [30] A similar dualism is
described by Mosos-Kolko et al. in adults with SSRI-induced
behavioural syndromes. [33] As we did in our study, Salisbury
et al. also discriminated between the effects of SSRI exposure and
maternal mood on neonatal neurobehaviour between days 1 to 21
after birth. [28] In the infants of women with major depressive
disorder, who had received SSRI treatment during pregnancy,
they found a lower quality of movement and more signs of central
nervous system stress. In contrast, in infants of women with only
major depressive disorder, without SSRIs they found the highest
quality of movements but lower attention scores. Our findings
confirm these different spectra at a more detailed level.
At the age of three to four months, 104 out of the 107 infants
showed normal overall GM quality, i.e. normal FMs. Only three
infants who had been exposed to SSRIs had abnormal FMs. We
know from other GM studies that abnormal GM quality at this age
is highly predictive of later neurological impairment. [21] We
speculated that an overall assessment of GM quality at this age
might not be sensitive enough to detect minor neurological
sequelae. For this purpose, the MOS and the concurrent
repertoire might be more revealing. When considering the
concurrent repertoire, we found that monotonous movements
were seen twice as often and that the MOS was significantly lower
in the exposed infants compared to the non-exposed infants.
Previously, it was reported that an abnormal concurrent repertoire
is related to minor neurological dysfunction in preterm-born
infants. [23] We speculated, therefore, that the lower MOSs and
the monotonous movements in our SSRI-exposed infants could be
indicative of permanently altered brain function due to exposure
to these antidepressants. Studies on the early effects of SSRI
exposure on infants aged three to four months are few. Only
Oberlander et al. described altered neonatal acute pain response
after SSRI exposure during pregnancy that persisted in two-
month-old infants in a prospective study. [34].
We recognize several limitations of our study. First, open
inclusion may have led to selection bias. The inclination to
participate in a study considering the possible negative effects of
SSRI exposure depends on the motivation of the parents. It is
unlikely, however, that this affected our findings since the
participants were unaware of the outcomes at the moment of
inclusion. Second, since the control group was not a healthy
control group, we cannot generalize the outcome of the infants in
the non-SSRI group to the general population. Although the
incidence of depression in the non-SSRI group was not extremely
high (21%) compared to the literature (10% to 25%) [1,4,5], the
incidence of anxiety was high (23%) compared to the literature
(7% to19%). [6,7] It was our aim to discriminate between effects of
SSRI exposure and effects due to maternal depression or anxiety
or both on the infants’ neurological functioning. A high incidence
of depression and anxiety in the non-SSRI group increased our
power to adjust for this confounder. A third limitation was that we
assessed maternal depression and anxiety using validated screening
questionnaires rather than a structured psychiatric interview, the
golden rule for diagnosing depression and anxiety. Possibly, as a
consequence, the incidence of depression and anxiety in our study
groups was slightly overestimated, which may have diluted
Table 4. Crude and adjusted odds ratios for abnormal general movements in the SSRI versus non-SSRI group.
Crude OR; 95% CI (p value) aORdepre+; 95% CI (p value) aORanx+; 95% CI (p value)
Abnormal GMs during the first week 3.0; 1.3–6.9 (0.008) 4.1; 1.6–10.5 (0.003) 4.2; 1.6–10.9 (0.003)
Monotonous movements at 3 to 4 months of
age
3.5; 1.5–8.6 (0.005)* 6.4; 2.1–19.2 (0.001)* 5.8; 1.9–17.7 (0.002)*




aORdepre+= adjusted odds ratio, corrected for maternal depression during 3
rd trimester, low-level maternal education (lower than vocational education), gestational age
below 38 weeks, birth weight below 2750 g, and sex.
aORanx+= adjusted odds ratio, corrected for maternal anxiety during 3
rd trimester, low-level maternal education (lower than vocational education), gestational age
below 38 weeks, birth weight below 2750 g, and sex.
*also corrected for paternal depression and anxiety at the infant’s age of 3 to 4 months.
doi:10.1371/journal.pone.0064654.t004
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estimates somewhat. Finally, we assessed maternal mood during
pregnancy in the third trimester only. Therefore, we might have
missed depression and anxiety during the first or second trimester,
while stress early in pregnancy can also affect neurological
outcome of the infant.
Our results have important implications. Clinically, physicians
should inform parents about the advantages and disadvantages of
taking SSRIs during pregnancy, and about the fact that SSRIs
have an independent effect on their infant’s developing brain.
SSRI exposure can influence neurological function of the foetus,
not transiently, as seen during the first days after birth, but also
later, at least at the age of three to four months. Physicians should
be aware that prescriptions should be limited to those women who
have an indication for prescription after careful evaluation by
professionals followed by pre-pregnancy advice in case of child
wish. We plea for centres with outpatient facilities in which
paediatricians, obstetricians and psychiatrists collaborate.
As far as research is concerned, our study needs to be replicated,
preferably including women with anxiety and depression disorders
confirmed by a structured psychiatric interview. In addition, data
on long-term neurological outcome of the infants are needed. For
this purpose we are planning to reassess the children at two-and-a-
half and seven years of age as part of this on-going SMOK trial.
In conclusion, prenatal exposure to SSRIs probably has
negative effects on the early neurological functioning of the infant,
irrespective of maternal mental state. Given the high rates of SSRI
Figure 2. Motor optimality scores in the SSRI and non-SSRI groups, clustered by maternal depression and anxiety. Motor optimality
scores during the first week (A, B) and at 3 to 4 months (C, D) in the SSRI and non-SSRI groups, clustered by maternal depression and anxiety during
pregnancy. The data in the graphs are presented as box-and-whisker plots. The boxes represent the individual values between the 25th and 75th
centile (interquartile range, IQR), the whiskers represent the range of the values, with the exception of outliers. Significant differences were tested
with the Mann-Whitney test. MOS=motor optimality score.
doi:10.1371/journal.pone.0064654.g002
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prescriptions to pregnant women (2% to13%)[8,9], this may have
considerable consequences for public health.
Supporting Information
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